Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
ONTARGET - Ongoing telmisartan alone and in combination with ramipril global endpoint trial und TRANSCEND - Telmisartan randomized assessment study in ACE-I intolerant subjects with cardiovascular disease (30 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 6: ONTARGET - from HOPE to ONTARGET Abb. 7: ONTARGET - the HOPE study Abb. 8: HOPE study results: primary end point Aktuelles Bild - Abb. 9: HOPE study results: secondary end point Abb. 10: ONTARGET - Rationale Abb. 11: ONTARGET - rationale Abb. 12: ONTARGET - rationale Zum letzten Bild
Abbildung 9: HOPE study results: secondary end point
All-cause mortality was reduced by 16% in ramipril-treated patients compared with placebo-treated patients (p=0.005). [7] Significantly fewer patients in the ramipril group than in the placebo group underwent revascularization (742 vs 852 patients, respectively, 15% reduction; p=0.002). There was a trend towards fewer hospitalizations for heart failure in the ramipril group (141 vs 160 patients, 12% reduction; p=0.25). The incidence of complications relating to diabetes was decreased with ramipril treatment by 16% (299 vs 354 patients; p=0.03). 7. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153.
 
HOPE study results: secondary end point
Vorheriges Bild Nächstes Bild   


Abbildung 9: HOPE study results: secondary end point
All-cause mortality was reduced by 16% in ramipril-treated patients compared with placebo-treated patients (p=0.005). [7] Significantly fewer patients in the ramipril group than in the placebo group underwent revascularization (742 vs 852 patients, respectively, 15% reduction; p=0.002). There was a trend towards fewer hospitalizations for heart failure in the ramipril group (141 vs 160 patients, 12% reduction; p=0.25). The incidence of complications relating to diabetes was decreased with ramipril treatment by 16% (299 vs 354 patients; p=0.03). 7. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung